These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 34366353)

  • 1. Serum Daytime Melatonin Levels Reflect Cerebrospinal Fluid Melatonin Levels in Alzheimer's Disease but Are Not Correlated with Cognitive Decline.
    Nous A; Wittens MMJ; Vermeiren Y; De Deyn PP; Van Broeckhoven C; Nagels G; Smolders I; Engelborghs S
    J Alzheimers Dis; 2021; 83(2):693-704. PubMed ID: 34366353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does serum uric acid act as a modulator of cerebrospinal fluid Alzheimer's disease biomarker related cognitive decline?
    Ye BS; Lee WW; Ham JH; Lee JJ; Lee PH; Sohn YH;
    Eur J Neurol; 2016 May; 23(5):948-57. PubMed ID: 26917248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal changes of CSF biomarkers in Alzheimer's disease.
    Seppälä TT; Koivisto AM; Hartikainen P; Helisalmi S; Soininen H; Herukka SK
    J Alzheimers Dis; 2011; 25(4):583-94. PubMed ID: 21460434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type.
    Popp J; Wolfsgruber S; Heuser I; Peters O; Hüll M; Schröder J; Möller HJ; Lewczuk P; Schneider A; Jahn H; Luckhaus C; Perneczky R; Frölich L; Wagner M; Maier W; Wiltfang J; Kornhuber J; Jessen F
    Neurobiol Aging; 2015 Feb; 36(2):601-7. PubMed ID: 25435336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between Adipokines and Biomarkers of Alzheimer's Disease: A Cross-Sectional Study.
    Letra L; Matafome P; Rodrigues T; Duro D; Lemos R; Baldeiras I; Patrício M; Castelo-Branco M; Caetano G; Seiça R; Santana I
    J Alzheimers Dis; 2019; 67(2):725-735. PubMed ID: 30689587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum but not cerebrospinal fluid levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) are increased in Alzheimer's disease.
    Johansson P; Åberg D; Johansson JO; Mattsson N; Hansson O; Ahrén B; Isgaard J; Åberg ND; Blennow K; Zetterberg H; Wallin A; Svensson J
    Psychoneuroendocrinology; 2013 Sep; 38(9):1729-37. PubMed ID: 23473966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased neurogranin concentrations in cerebrospinal fluid of Alzheimer's disease and in mild cognitive impairment due to AD.
    Sanfilippo C; Forlenza O; Zetterberg H; Blennow K
    J Neural Transm (Vienna); 2016 Dec; 123(12):1443-1447. PubMed ID: 27531278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum Adiponectin in Alzheimer's Disease (AD): Association with AD Biomarkers and Cognitive Outcome.
    Kim H; Jun S; Kim BS; Kim IJ;
    J Alzheimers Dis; 2021; 84(3):1163-1172. PubMed ID: 34633322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apolipoprotein A1 in Cerebrospinal Fluid and Plasma and Progression to Alzheimer's Disease in Non-Demented Elderly.
    Slot RE; Van Harten AC; Kester MI; Jongbloed W; Bouwman FH; Teunissen CE; Scheltens P; Veerhuis R; van der Flier WM
    J Alzheimers Dis; 2017; 56(2):687-697. PubMed ID: 28035918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
    Mathys J; Gholamrezaee M; Henry H; von Gunten A; Popp J
    Exp Gerontol; 2017 Dec; 100():45-53. PubMed ID: 29054536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced cerebrospinal fluid level of thyroxine in patients with Alzheimer's disease.
    Johansson P; Almqvist EG; Johansson JO; Mattsson N; Hansson O; Wallin A; Blennow K; Zetterberg H; Svensson J
    Psychoneuroendocrinology; 2013 Jul; 38(7):1058-66. PubMed ID: 23159010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal fluid PKR level predicts cognitive decline in Alzheimer's disease.
    Dumurgier J; Mouton-Liger F; Lapalus P; Prevot M; Laplanche JL; Hugon J; Paquet C;
    PLoS One; 2013; 8(1):e53587. PubMed ID: 23320095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positive Association Between Cognitive Function and Cerebrospinal Fluid Orexin A Levels in Alzheimer's Disease.
    Shimizu S; Takenoshita N; Inagawa Y; Tsugawa A; Hirose D; Kaneko Y; Ogawa Y; Serisawa S; Sakurai S; Hirao K; Kanetaka H; Kanbayashi T; Imanishi A; Sakurai H; Hanyu H
    J Alzheimers Dis; 2020; 73(1):117-123. PubMed ID: 31744010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
    Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
    JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CSF and blood Kallikrein-8: a promising early biomarker for Alzheimer's disease.
    Teuber-Hanselmann S; Rekowski J; Vogelgsang J; von Arnim C; Reetz K; Stang A; Jöckel KH; Wiltfang J; Esselmann H; Otto M; Tumani H; Herring A; Keyvani K
    J Neurol Neurosurg Psychiatry; 2020 Jan; 91(1):40-48. PubMed ID: 31371645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decreased levels of guanosine 3', 5'-monophosphate (cGMP) in cerebrospinal fluid (CSF) are associated with cognitive decline and amyloid pathology in Alzheimer's disease.
    Ugarte A; Gil-Bea F; García-Barroso C; Cedazo-Minguez Á; Ramírez MJ; Franco R; García-Osta A; Oyarzabal J; Cuadrado-Tejedor M
    Neuropathol Appl Neurobiol; 2015 Jun; 41(4):471-82. PubMed ID: 25488891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased Cerebrospinal Fluid Concentration of ZnT3 Is Associated with Cognitive Impairment in Alzheimer's Disease.
    Enache D; Pereira JB; Jelic V; Winblad B; Nilsson P; Aarsland D; Bereczki E
    J Alzheimers Dis; 2020; 77(3):1143-1155. PubMed ID: 32925049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
    Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
    Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating ethanolamine plasmalogen indices in Alzheimer's disease: Relation to diagnosis, cognition, and CSF tau.
    Kling MA; Goodenowe DB; Senanayake V; MahmoudianDehkordi S; Arnold M; Massaro TJ; Baillie R; Han X; Leung YY; Saykin AJ; Nho K; Kueider-Paisley A; Tenenbaum JD; Wang LS; Shaw LM; Trojanowski JQ; Kaddurah-Daouk RF;
    Alzheimers Dement; 2020 Sep; 16(9):1234-1247. PubMed ID: 32715599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced Cerebrospinal Fluid Concentration of Apolipoprotein A-I in Patients with Alzheimer's Disease.
    Johansson P; Almqvist EG; Bjerke M; Wallin A; Johansson JO; Andreasson U; Blennow K; Zetterberg H; Svensson J
    J Alzheimers Dis; 2017; 59(3):1017-1026. PubMed ID: 28697566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.